1
|
Loricera J, Castañeda S, Moriano C, Narváez J, Aldasoro V, Maiz O, Melero R, Villa I, Vela P, Romero-Yuste S, Callejas JL, de Miguel E, Galíndez-Agirregoikoa E, Sivera F, Fernández-López JC, Galisteo C, Ferraz-Amaro I, Sánchez-Martín J, Sánchez-Bilbao L, Calderón-Goercke M, Casado A, Hernández JL, González-Gay MA, Blanco R. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients. Ther Adv Musculoskelet Dis 2022; 14:1759720X221113747. [PMID: 35898567 PMCID: PMC9310329 DOI: 10.1177/1759720x221113747] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Accepted: 06/29/2022] [Indexed: 11/17/2022] Open
Abstract
Background: Visual involvement is the most feared complication of giant cell arteritis
(GCA). Information on the efficacy of tocilizumab (TCZ) for this
complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with TCZ, to evaluate its role in
the prevention of new visual complications and its efficacy when this
manifestation was already present before the initiation of TCZ. Design: This is an observational multicenter study of patients with GCA treated with
TCZ. Methods: Patients were divided into two subgroups according to the presence or absence
of visual involvement before TCZ onset. Visual manifestations were
classified into the following categories: transient visual loss (TVL),
permanent visual loss (PVL), diplopia, and blurred vision. Results: Four hundred seventy-one GCA patients (mean age, 74 ± 9 years) were treated
with TCZ. Visual manifestations were observed in 122 cases (26%), of which
81 were present at TCZ onset: PVL (n = 60;
unilateral/bilateral: 48/12), TVL (n = 17;
unilateral/bilateral: 11/6), diplopia (n = 2), and blurred
vision (n = 2). None of the patients without previous
visual involvement or with TVL had new episodes after initiation of TCZ,
while only 11 out of 60 (18%) patients with PVL experienced some
improvement. The two patients with diplopia and one of the two patients with
blurred vision improved. Conclusion: TCZ may have a protective effect against the development of visual
complications or new episodes of TVL in GCA. However, once PVL was
established, only a few patients improved.
Collapse
Affiliation(s)
- Javier Loricera
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - Santos Castañeda
- Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Catedra UAM-Roche, EPID-Future, UAM, Madrid, Spain
| | - Clara Moriano
- Department of Rheumatology, Complejo Asistencial Universitario de León, León, Spain
| | - Javier Narváez
- Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain
| | - Vicente Aldasoro
- Department of Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Olga Maiz
- Department of Rheumatology, Hospital Universitario de Donostia, San Sebastián, Spain
| | - Rafael Melero
- Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
| | - Ignacio Villa
- Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain
| | - Paloma Vela
- Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain
| | - Susana Romero-Yuste
- Department of Rheumatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - José L Callejas
- Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain
| | | | | | - Francisca Sivera
- Department of Rheumatology, Hospital Universitario de Elda, Alicante, Spain
| | | | - Carles Galisteo
- Department of Rheumatology, Hospital Parc Taulí, Barcelona, Spain
| | - Iván Ferraz-Amaro
- Department of Rheumatology, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain
| | | | - Lara Sánchez-Bilbao
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - Mónica Calderón-Goercke
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - Alfonso Casado
- Department of Ophthalmology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - José L Hernández
- Internal Medicine Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n, ES-39008 Santander, Spain
| | - Miguel A González-Gay
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Avda. Valdecilla s/n, ES-39008 Santander, Spain
| | - Ricardo Blanco
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Avda. Valdecilla s/n, ES-39008 Santander, Spain
| |
Collapse
|
2
|
Atienza-Mateo B, Prieto-Peña D, Vicente-Rabaneda EF, Blanco R, González-Gay MA, Castañeda S. Utility of tocilizumab in autoimmune eye diseases. Expert Opin Biol Ther 2022; 22:789-799. [DOI: 10.1080/14712598.2022.2066971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Belén Atienza-Mateo
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Diana Prieto-Peña
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | | | - Ricardo Blanco
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Miguel A. González-Gay
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
- Department of Medicine, University of Cantabria, Santander, Spain
- Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Santos Castañeda
- Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Madrid, Spain
- Cátedra UAM-Roche, EPID-Future, Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
3
|
Zhou P, Zhang J, Qi Y. The Efficacy of Glucocorticoids in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2022; 2022:2935992. [PMID: 35341003 PMCID: PMC8956449 DOI: 10.1155/2022/2935992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 01/30/2022] [Accepted: 02/02/2022] [Indexed: 11/17/2022]
Abstract
Background To evaluate the clinical effects and safety of glucocorticoids for patients with nonarteritic anterior ischemic optic neuropathy (NAION). Methods The databases MEDLINE, Embase, PubMed, Cochrane Database, and Web of Science were used to search for the relevant studies, and full-text articles that reported on the evaluation of glucocorticoids vs. no-treatment or placebo for patients with NAION. Review Manager 5.4 was used to estimate the pooled effects of the results among selected studies. Forest plots, funnel plots, and Begg's rank correlation were also performed on the included articles. Results A total of 983 patients were contained in the 9 studies that satisfied the eligibility criteria. The meta-analysis showed that, compared with the control group, the glucocorticoid group had significantly improved the VA (MD: -0.25, 95% CI [-0.45, -0.05], P = 0.02), VF (MD: -0.50, 95% CI [-0.94, -0.07], P = 0.02), and RNFL (MD: -14.10, 95% CI [-26.41, -1.79], P = 0.02) in NAION patients and had a high improvement rate of VA (RR 1.31, 95% CI [1.12, 1.52], P = 0.0005). No significant publication bias was observed in our study. Discussion. Our research preliminarily confirmed the effectiveness of glucocorticoids for NAION treatment, but more high-quality RCTs focusing on the hormone adverse reactions should be performed to verify our conclusions.
Collapse
Affiliation(s)
- Pingping Zhou
- Department of Ophthalmology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China
| | - Jian Zhang
- Department of Ophthalmology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China
| | - Yanxiu Qi
- Department of Ophthalmology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China
| |
Collapse
|